Combination BRAF and MEK inhibition provides HRQoL advantage vs BRAF inhibitor monotherapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • A study of health-related quality of life scores from a phase III study in BRAF Val600 mutation-positive metastatic melanoma found combination dabrafenib + trametinib to provide benefits over vemurafenib monotherapy 
Study Design
  • Pre-specified prospective analysis of HRQoL from a Phase III, open-label, randomised study (COMBI-v) of patients with BRAF Val600 mutation-positive metastatic melanoma
  • Study population: 704 patients
  • Treatment: 352 patients were randomized to receive dabrafenib (150 mg twice-daily) and trametinib (2 mg once-daily); 352 patients were randomized to receive vemurafenib monotherapy (960 mg twice-daily) orally as first-line therapy
  • Key measurements: HRQoL in the intention-to-treat population with the European Organisation for Research and Treatment of Cancer quality of life (EORTC QLQ-C30), EuroQoL-5D (EQ-5D), and Melanoma Subscale of the Functional Assessment of Cancer Therapy-Melanoma (FACT-M)
Key Results
  • High rate of questionnaire completion: 95% at baseline, 80% at follow-up ...